scispace - formally typeset
R

Rachel Brandstadter

Researcher at Icahn School of Medicine at Mount Sinai

Publications -  24
Citations -  448

Rachel Brandstadter is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Medicine & Multiple sclerosis. The author has an hindex of 8, co-authored 21 publications receiving 257 citations. Previous affiliations of Rachel Brandstadter include University of Pennsylvania & Corinne Goldsmith Dickinson Center for Multiple Sclerosis.

Papers
More filters
Journal ArticleDOI

COVID-19 and MS disease-modifying therapies.

TL;DR: Concerns regarding the effect of MS disease-modifying therapies (DMTs) on the expression of coronavirus 2019 (COVID-19) are addressed while the data are being accumulated.
Journal ArticleDOI

Disease-modifying therapies alter gut microbial composition in MS.

TL;DR: Administration of GA or DMF is associated with differences in gut microbial composition in patients with MS, and it is hypothesize that the findings may highlight mechanisms of pathophysiology and potential therapeutic intervention requiring further investigation.
Journal ArticleDOI

The use of natalizumab for multiple sclerosis.

TL;DR: Natalizumab’s high efficacy and favorable tolerability profile have led to a broad use by MS physicians, as both first- and second-line treatments, and pragmatic considerations regarding its use in clinical practice are finished.
Journal ArticleDOI

Dissociable cognitive patterns related to depression and anxiety in multiple sclerosis.

TL;DR: Consistent mood–cognition relationships were identified in two independent cohorts of MS patients, suggesting that cognitive correlates of anxiety and depression are separable, and may support more precise models to inform treatment development.